Drug intelligence / Profile preview

OCTR

Development stage: Unknown
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intraperitoneal, Intravenous

Overview

OCTR is a bispecific antibody (BsmAb) designed for retargeted T cell-mediated lysis, primarily investigated for advanced ovarian carcinoma. It functions by simultaneously binding to the CD3 receptor on T cells and the folate receptor expressed on ovarian carcinoma cells. This dual targeting mechanism aims to redirect the patient's own T cells to specifically recognize and destroy cancer cells, offering a novel therapeutic approach for patients who have relapsed after induction chemotherapy.

Targets

CD3 (T-cell surface glycoprotein CD3)FOLR1 (FRα)

Beyond the preview

Go deeper on OCTR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OCTR.

Explore the full profile